Capodici, A., De Amicis, R., et al
Astaxanthin Rescues Memory Impairments in Rats with Vascular Dementia by Protecting Against Neuronal Death in the Hippocampus
In clinical trials of Wegovy (FDA-approved semaglutide), participants achieved an average weight loss of approximately 15% over 68 weeks, with some participants achieving up to 20% with continued treatment and adherence, when combined with diet and exercise
When you have an NAD consultation and treatment, you should always be able to rest easy, knowing that there will be medical supervision
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist, which means that it works by mimicking the effects of GLP-1, a hormone produced in the gut that stimulates insulin secretion, reduces glucagon secretion, and slows down gastric emptying